Waters Corporation ($WAT) Stock Forecast: Up 5.9% Today

What is Waters Corporation?

Waters Corporation (WAT) is a leading provider of analytical instruments, known for its contributions to drug discovery, material science, and environmental testing. The company's recent FDA approval for an at-home cervical cancer screening kit has garnered attention and is expected to enhance early detection rates.

Why is Waters Corporation going up?

WAT stock is up 5.9% on Apr 8, 2026 15:13

• The bullish movement in Waters Corp's stock (WAT) can be attributed to the following factors:
• Approval of Waters' at-home cervical cancer screening kit is a significant milestone, enhancing the company's product portfolio and potentially increasing its market share in the healthcare sector.
• The approval is expected to drive revenue growth as the kit allows for convenient at-home sample collection, catering to the un/under-screened population, thereby addressing a critical healthcare need.
• Waters Corp's strong market position in essential industries like drug discovery and environmental testing, coupled with its diversified portfolio and recurring revenue model, provides investors with confidence in its long-term growth prospects.
• Despite facing risks such as supply chain disruptions, the company's strategic focus on innovation and its role in critical industries position it favorably for sustained success in the market.

WAT Price Chart

WAT Technical Analysis

WAT News

US FDA approves Waters' at‑home cervical cancer screening kit

The U.S. FDA has approved Waters' at-home cervical cancer screening kit, which is designed to detect high-risk human papillomavirus (HPV) types. This approval is expected to improve early detection and reduce deaths from cervical cancer, particularly as about 60% of cases occur in individuals who are not screened regularly. The kit allows patients to collect samples at home for lab testing, and Waters plans to make it available nationwide by prescription, with coverage anticipated from private insurance and federal programs.

https://www.reuters.com/legal/litigation/us-fda-approves-waters-athome-cervical-cancer-screening-kit-2026-04-08/

FDA clears at-home HPV kit as 60% of cervical cancer cases hit unscreened people

Waters Corporation announced FDA clearance of its Onclarity HPV Self-Collection Kit and approval of the BD Onclarity HPV Assay for at-home use. This development aims to significantly increase access to cervical cancer screening, particularly for the 60% of cases occurring in unscreened or under-screened individuals. The kit, which features comprehensive HPV genotyping, will be available by prescription in the coming months and is expected to be covered by private insurance, Medicaid, and Medicare.

https://www.stocktitan.net/news/WAT/waters-announces-fda-clearance-of-the-most-comprehensive-at-home-sj429zyga7vo.html

Waters Corp stock: What investors need to know in today's market

Waters Corp, a leader in analytical instruments like chromatography and mass spectrometry, offers stability for investors due to its essential role in drug discovery, material science, and environmental testing. The company's diversified portfolio, global footprint, and recurring revenue model from consumables provide a competitive edge. While facing risks like supply chain disruptions, its strong market position in critical industries makes it an attractive long-term investment, particularly with ongoing global R&D spending and emerging market growth.

https://www.ad-hoc-news.de/boerse/news/ueberblick/waters-corp-stock-what-investors-need-to-know-in-today-s-market/69104060

Azenta names Trey Martin president of Multiomics business By Investing.com

Azenta, Inc. has appointed Trey Martin as President of its Multiomics business, effective April 6, 2026. Martin, previously CEO of Maravai Life Sciences and holding senior roles at Danaher Corporation, brings over 30 years of experience in life sciences and genomics platforms. This leadership change follows a period of stock volatility for Azenta, despite recent positive developments like an acquisition and strategic partnerships.

https://uk.investing.com/news/company-news/azenta-names-trey-martin-president-of-multiomics-business-93CH-4596209

Waters Corp. stock outperforms competitors on strong trading day

Waters Corp. (WAT) saw its stock rise by 1.08% to $307.38 on Tuesday, outperforming the S&P 500 Index which gained 0.08%, and the Dow Jones Industrial Average which fell 0.18%. The company's shares closed 25.78% below its 52-week high of $414.15 achieved on November 25th.

https://www.marketwatch.com/data-news/waters-corp-stock-outperforms-competitors-on-strong-trading-day-da7df8ec-fa96ee827dd5

Trending Today

Heating Oil ($HEATOIL) Commodity Forecast: Up 5.2% Today

Chewy Inc ($CHWY) Stock Forecast: Up 5.2% Today

Cadence Design Systems Inc. ($CDNS) Stock Forecast: Up 5.2% Today

Fortune Brands Innovations Inc. ($FBIN) Stock Forecast: Down 5.3% Today

A.O. Smith Corporation ($AOS) Stock Forecast: Down 6.4% Today

Credo Technology Group ($CRDO) Stock Forecast: Up 5.6% Today

Live Nation Entertainment Inc. ($LYV) Stock Forecast: Down 5.5% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 5.4% Today

Tesla Inc. ($TSLA) Stock Forecast: Up 7.4% Today

V.F. Corporation ($VFC) Stock Forecast: Up 5.0% Today

Waters Corporation Price History

13.01.2026 - WAT Stock was up 5.3%

• Waters Corporation (WAT) experienced a strong bullish movement today, potentially driven by the following factors:
• Despite a recent 19% decline in the stock price, analysts are optimistic about a turnaround, with the stock being in oversold territory and showing signs of rebound potential.
• The company reported robust Q4 and full-year 2025 results, with strong sales and earnings, as well as providing optimistic guidance for 2026.
• Waters' recent acquisition of BD Biosciences and Diagnostic Solutions is expected to contribute significantly to revenue growth and synergies, boosting investor confidence in the company's future prospects.
• The positive sentiment surrounding Waters Corporation contrasts with the news about another company, which has been undergoing changes such as the sale of its Life Sciences business and facing mixed analyst reactions, potentially diverting investor attention towards WAT's more promising outlook.

06.00.2026 - WAT Stock was up 5.2%

• Received an Outperform rating with projections of significant EPS growth by 2030 due to synergies from the BD Biosciences and Diagnostics Solutions acquisition.
• Strong Q3 2025 financial results surpassed analyst expectations, leading to multiple upgrades and price target increases.
• Estimated intrinsic value suggests the current share price is trading at similar levels to fair value, indicating a balanced valuation.
• The combination of favorable analyst ratings, strategic acquisitions, and solid financial performance likely contributed to the bullish movement in the stock today.

05.00.2026 - WAT Stock was up 1.7%

• An analyst initiated coverage on Waters Corp with an Outperform rating, referencing synergies from the BD acquisition as a primary growth driver, leading to a positive market sentiment.
• The alignment of Waters' intrinsic value with its current share price suggests investors view the stock as fairly valued, contributing to the bullish momentum.
• Despite a challenging year for capital spending, Waters Corp's strategic shift towards recurring revenue streams and focus on high-value biopharma and QA/QC workflows have instilled confidence among analysts, supporting the bullish trend.
• The company's disciplined approach to rebuilding, integration of core hardware with software and data analytics, and emphasis on becoming a resilient platform provider have positioned it well for potential future growth, further boosting investor optimism and driving the bullish market movement.

15.06.2025 - WAT Stock was down 5.8%

• The bearish movement in Waters Corporation's stock today can be attributed to the market's reaction to the collaboration news with Becton Dickinson.
• Investors might be concerned about the long-term implications of the $17.5B deal and the ambitious revenue targets set for 2030, which could lead to uncertainty and selling pressure on Waters' stock.
• The market might be interpreting the partnership as a potential risk factor for Waters' standalone growth prospects, leading to a pessimistic sentiment among investors and triggering the bearish movement in the stock price.
• Investors may be waiting for more clarity on how the collaboration will impact Waters' financials and strategic direction before reassessing the stock's valuation and growth potential.

08.03.2026 - WAT Stock was up 5.9%

• The bullish movement in Waters Corp's stock (WAT) can be attributed to the following factors:
• Approval of Waters' at-home cervical cancer screening kit is a significant milestone, enhancing the company's product portfolio and potentially increasing its market share in the healthcare sector.
• The approval is expected to drive revenue growth as the kit allows for convenient at-home sample collection, catering to the un/under-screened population, thereby addressing a critical healthcare need.
• Waters Corp's strong market position in essential industries like drug discovery and environmental testing, coupled with its diversified portfolio and recurring revenue model, provides investors with confidence in its long-term growth prospects.
• Despite facing risks such as supply chain disruptions, the company's strategic focus on innovation and its role in critical industries position it favorably for sustained success in the market.

04.10.2025 - WAT Stock was up 6.7%

• Waters Corporation (WAT) exceeded Q3 earnings and revenue estimates, indicating strong financial performance.
• The positive surprises in earnings and revenue suggest that the company's products and services are in high demand.
• Investors are likely optimistic about Waters' future prospects, leading to a bullish movement in the stock price.
• The strong quarterly results may attract more investors and analysts' attention, further boosting the stock's performance in the near term.

25.02.2026 - WAT Stock was down 0.7%

• Waters Corporation (WAT) experienced a bearish movement today, possibly influenced by the company's recent issuance of $3.5 billion in senior notes to refinance a term loan.
• The market may have reacted negatively to the significant debt increase, which could raise concerns about Waters' financial leverage and future cash flows.
• Despite the bearish movement, investors should keep an eye on Agilent Technologies Inc. (A) as its innovative chromatography solutions launch has boosted investor confidence and positioned the company for sustained revenue growth in the life sciences market.
• The sale of Alphabet Inc. (GOOGL) shares by Representative Thomas H. Kean, Jr. may have also contributed to market jitters, reflecting potential profit-taking activities among institutional investors.

18.01.2026 - WAT Stock was up 5.0%

• Waters Corporation's bullish movement can be attributed to the launch of their new 1 mm I.D. liquid chromatography (LC) columns with MaxPeak Premier Technology. This innovation promises higher sensitivity, reduced sample usage by 75%, and decreased solvent consumption by up to four times compared to traditional columns, catering to high-throughput bioseparations and pharmaceutical applications.
• The positive market sentiment towards Waters Corporation could also be influenced by the overall growth projections of the Gas Chromatography Systems Market, which is expected to reach US$7.20 billion by 2032. This indicates a rising demand for advanced analytical instrumentation, benefiting companies like Waters Corporation.
• The emphasis on technological advancements by key players in the gas chromatography market, such as Thermo Fisher Scientific and Agilent Technologies, further highlights the potential for growth and innovation in the sector. Waters Corporation's introduction of cutting-edge technology aligns with this trend, likely contributing to the bullish movement of their stock.
• Waters Corporation's focus on enhancing sensitivity, sample recovery, and data quality through their new LC columns positions them well to capitalize on the increasing demand for analytical solutions in various industries, potentially driving further positive momentum in their stock performance.

12.01.2026 - WAT Stock was down 5.3%

• Waters Corporation (WAT) experienced a bearish movement following a price target downgrade by an analyst from Wells Fargo.
• The downgrade may be linked to the upcoming merger with BD's life science and diagnostics business, leading to investor uncertainty about the combined entity's future prospects.
• Despite the downgrade, analysts from Guggenheim and HSBC have issued positive ratings and higher price targets, indicating varying opinions on the merger's potential success.
• Investor behavior suggests a keen interest in monitoring the merger's developments and its possible impact on Waters Corporation's growth in the competitive life sciences industry.

12.01.2026 - WAT Stock was down 5.5%

• Waters Corporation's stock slipped despite beating Q4 expectations, indicating investor disappointment in the company's outlook. This could have contributed to the bearish movement.
• The news of Becton, Dickinson and Company (BDX) raising its price target and reporting strong Q1 results might have shifted investor focus towards BDX, leading to a relative sell-off of WAT shares.
• The merger of BD's Biosciences & Diagnostics business with Waters Corporation could have caused uncertainty among investors regarding the future prospects of Waters Corporation, impacting its stock performance negatively.
• Despite Waters Corporation's recent challenges, focusing on strategic growth opportunities and improving outlook could help regain investor confidence and stabilize the stock price in the future.

27.02.2026 - WAT Stock was down 5.5%

• Waters Corp stock faced a bearish movement possibly due to growth challenges, despite favorable sector tailwinds.
• The company's mixed recent performance and analyst ratings leaning towards a "Moderate Buy" might have contributed to investor uncertainty and selling pressure.
• The bearish trend could also be influenced by the overall slowdown in the life sciences sector, indicating broader industry challenges impacting companies like Waters Corp.
• Investors may be cautious about the company's ability to navigate these growth challenges and maintain its competitive position in the market, leading to the bearish movement in the stock.

01.07.2025 - WAT Stock was down 6.4%

• The bearish movement in WAT today could be due to profit-taking by investors after a period of strong growth.
• Despite the positive expectations for the upcoming earnings report, market sentiment may have shifted, leading to a sell-off of WAT shares.
• It's possible that some investors are cautious about the company's future outlook or there may be broader market concerns impacting WAT's stock price.
• Overall, the bearish movement in WAT today may be a short-term correction rather than a reflection of the company's long-term prospects.